PARSIPPANY, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of AR-67 in adult patients with Myelodysplastic Syndrome (MDS) who have failed prior therapies. MDS is a group of pre-malignant blood disorders marked by abnormal production of blood cells by the bone marrow.
